Explore facts and recommendations for pharmacological treatments for rare renal disorders.
We didn't find any resources that match your selection.
Please adjust your filter(s) and try again.
PHYOX Clinical Development Program
An overview of the PHYOX clinical development program evaluating nedosiran for the treatment of primary hyperoxaluria.
PHYOX2 infographic
This infographic provides an overview of PHYOX2, the pivotal randomized study of nedosiran in PH1 or PH2
PHYOX3 infographic
This infographic summarizes the safety and efficacy of nedosiran in patients with PH1 based 2.5 year interim analysis of the PHYOX3 trial
Rare Renal Disorders
Rare Renal Disorders
Continuing Education
Find accredited opportunities in rare renal disorders education.
Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.